• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs
【24h】

Validate Mitotic Checkpoint and Kinetochore Motor Proteins in Breast Cancer Cells as Targets for the Development of Novel Anti-Mitotic Drugs

机译：验证乳腺癌细胞中的有丝分裂检查点和动粒运动蛋白作为新型抗有丝分裂药物开发的目标

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Drugs that inhibit microtubule functions are one of many anti- neoplastic drugs that are used to combat breast and other cancers. Taxol and vincristine are microtubule poisons that block the proper function of microtubules that are essential for a broad spectrum of motile biological processes that include cell division, vesicle transport, cell shape, and flagella functions. For rapidly proliferating cancer cells, anti-microtubule drugs offers a highly effective means to block cell division and thus stop tumor growth. Nevertheless, these drugs block other microtubule dependent processes that adversely affect the functions of many non-dividing cells. Furthermore, there is the complication that the cancer cells can develop multi- drug resistance that makes them refractile to conventional anti-neoplastic agents. The identification of novel drugs with increased selectivity towards mitotic processes and act synergistically with existing anti-microtubule drugs should enhance and refine the modalities used to treat breast cancer patients. Our interest in the molecular and biochemical mechanisms that are central to mitosis in human cells has led to the identification of novel proteins and pathways that are suited for designing highly specific anti-mitotic drugs. The objective of this proposal is to disrupt such pathways in established breast cancer cell lines to validate them as suitable targets for developing new anti- mitotic drugs.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号